The Antibiotic Last Line of Defense Against Gonorrhea Just Lost More Ground: WHO Data Shows Sixfold Resistance Rise and U.S. Is Running Out of Options

WHO EGASP data show ceftriaxone resistance in gonorrhea rose more than sixfold globally from 2022 to 2024. Ceftriaxone is the only U.S.-recommended gonorrhea treatment. New pipeline drugs show promise but are not yet approved.